Author + information
- Hidekatsu Fukuta and
- Nobuyuki Ohte
Influenza infection is associated with increased risk for mortality and hospitalization in heart failure patients. Although the prognostic benefit of influenza vaccination in heart failure patients has been examined in several studies, the results are inconsistent due partly to small sample sizes. We aimed to conduct a meta-analysis of the effect of influenza vaccination on mortality and hospitalization in heart failure patients.
The search of electronic databases identified 5 observational cohort studies (78,882 patients; mean age, 64-75 years; men, 39%-79%; follow-up duration, 1-4 years) but no randomized controlled trials on the effect of influenza vaccination on mortality or hospitalization in heart failure patients.
Pooled analysis of confounder-adjusted hazard ratio showed that influenza vaccination was associated with reduced risk for mortality during influenza season (risk ratio [95% CI] = 0.52 [0.39-0.69]) and during non-influenza season (0.79 [0.69-0.90]). Influenza vaccination was associated with lower risk for cardiovascular hospitalization (risk ratio [95% CI] = 0.78 [0.68-0.89]) but not for all-cause hospitalization (1.00 [0.90-1.11]) during influenza season.
Our meta-analysis suggests the potential mortality benefit of influenza vaccination in heart failure patients. Large-scale randomized controlled trials should be planned to confirm our observed potential survival benefit of influenza vaccination in these patients.
Poster Hall, Hall A/B
Sunday, March 11, 2018, 3:45 p.m.-4:30 p.m.
Session Title: Cardiomyopathies: Assessment and Outcomes
Abstract Category: 13. Heart Failure and Cardiomyopathies: Clinical
Presentation Number: 1238-089
- 2018 American College of Cardiology Foundation